Table 2.

In vitro cytotoxicity (IC_50, µM) of the tested compound and DOX against human normal cell line WI38.

Comp. no.	WI38a IC50 (µM)	Comp. no	WI38 IC50 (µM)
3	78.52 ± 3.8	9	48.18 ± 2.8
5	63.97 ± 3.1	10	67.74 ± 3.4
7	> 100	11	43.25 ± 2.9
8	48.18 ± 2.8	12	56.45 ± 3.2
DOX	4.50 ± 0.2

^aHuman lung fibroblast (WI38).

IC₅₀: compound concentration required to inhibit normal cell proliferation by 50% (mean ± SD, n = 3).

IC₅₀ (µM). ^ϯ1–10 (very strong), *11–25 (strong), 26–50 (moderate), 51–100 (weak), > 100 (non-toxic). DOX doxorubicin as a reference drug.